The place of pegvisomant in the management of acromegaly

Expert Opinion on Investigational Drugs

Volumn 10, Issue 9, 2001, Pages 1725-1735

  Parkinson, C ^a   Trainer, P J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Acromegaly; Pegvisomant

Indexed keywords

ANGIOPEPTIN; ARGININE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLYCINE; GROWTH HORMONE; GROWTH HORMONE DERIVATIVE; GROWTH HORMONE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; OCTREOTIDE; PEGVISOMANT; PLACEBO; QUINAGOLIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACROMEGALY; ALPHA HELIX; AMINO ACID SUBSTITUTION; ARTICLE; CELL LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIMERIZATION; DISEASE CONTROL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SYNTHESIS; FLATULENCE; GALLSTONE FORMATION; GENETIC ENGINEERING; GROWTH HORMONE BLOOD LEVEL; HORMONE ACTION; HUMAN; HYPOPHYSIS TUMOR; LIVER FUNCTION; MALE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREVENTION; RANDOMIZED CONTROLLED TRIAL; TUMOR GROWTH;

ACROMEGALY; ANIMALS; CELL DIVISION; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMAN GROWTH HORMONE; HUMANS; PITUITARY NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, SOMATOTROPIN;

EID: 0034852068     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.9.1725     Document Type: Article

References (117)

1. Epidemiology of acromegaly in the Newcastle region
2. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984
3. Acromegaly
4. Acromegaly
5. Embryonic stem cells express growth hormone receptors: Regulation by retinoic acid
6. Growth hormone and its receptors in the central nervous system-location and functional significance
7. Localization of the growth hormone receptor, identified by immunocytochemistry, in second trimester human fetal tissues and in placenta throughout gestation
8. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: Correlation with the degree of growth hormone hypersecretion
9. Evaluation of acromegaly by radioimmunoassay of somatomedin-C
10. Homeostasis model assessment: Insulin resistance and B cell-function from fasting plasma glucose and insulin concentrations in man
11. Demonstration of long-term improvement in subjective and objective assessments of well-being in patients with acromegaly treated with pegvisomant
12. Effect of pegvisomant-induced normalization of serum IGF-I on IGF-II, IGF binding proteins and insulin resistance in active acromegaly
13. Mortality in acromegaly
14. An audit of outcome of treatment in acromegaly
15. Determinants of clinical outcome and survival in acromegaly
16. Clinical manifestations of acromegaly
17. Mortality and cancer incidence in acromegaly: A Retrospective Cohort Study
18. Transspenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initial outcome and long-term results
19. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly
20. Criteria for cure of acromegaly: A consensus statement
21. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure
22. Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience
23. The Birmingham pituitary database: Auditing the outcome of the treatment of acromegaly
24. The outcome of surgery for acromegaly: The need for a specialist pituitary surgeon for all types of growth hormone (GH) secreating adenomas
25. Outcome of surgery for acromegaly-the experience of a dedicated pituitary surgeon
26. Results of radiotherapy in the treatment of acromegaly: Lack of ophthalmologic complications
27. Hypopituitarism following radiation therapy of pituitary adenomas
28. External irradiation of growth hormone producing pituitary adenomas: Prolactin as a marker of hypothalamic and pituitary effects
29. Conventional supervoltage irradiation is an effective treatment for acromegaly
30. Radiation therapy of acromegaly
31. Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels
32. Comparison of radiosurgery treatment modalities based on physical dose distributions
33. Four years' experiences in the treatment of pituitary adenomas with gamma knife radiosurgery
34. Role of gamma knife therapy in the management of pituitary tumors
35. Stereotactic radiosurgery for recurrent surgically treated acromegaly: Comparison with fractionated radiotherapy
36. Pituitary adenoma radiotherapy - When, who and how?
37. Long-term treatment of acromegaly with bromocriptine
38. Treatment of actomegaly with dopamine agonists
39. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: A comparison with bromocriptine
40. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: Clinical and biochemical effects
41. Bromocriptine therapy in acromegaly: Use in patients resistant to conventional therapy and effect on serum levels of somatomedin C
42. Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly
43. CV 205-502 in acromegaly
44. Effect of different dopaminergic agents in the treatment of acromegaly
45. Cabergoline in the treatment of acromegaly: A study in 64 patients
46. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients
47. Cabergoline treatment of acromegaly: A preliminary dose finding study
48. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients
49. Distribution of somatostatin receptors in normal and tumor tissue
50. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney
51. Somatostatin receptors, an expanding gene family: Cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase
52. Molecular cloning and functional expression of a brain-specific somatostatin receptor
53. Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28
54. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
55. Somatostatin
56. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5)
57. Molecular pharmacology of somatostatin-receptor subtypes
58. Octreotide treatment of acromegaly. A randomized, multicenter study
59. A prospective multicenter octreotide dose response study in the treatment of acromegaly
60. Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients-a clinical research center study
61. Octreotide
62. Therapy of acromegaly with sandostatin: The predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'
63. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide
64. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients
65. The Sandostatin LSR Group. Results of a European Multicentre study with Sandostatin LAR in acromegalic patients
66. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly
67. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicenter study
68. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide
69. Octreotide-associated biliary tract dysfunction and gallstone formation: Pathophysiology and management
70. Gallstones during octreotide therapy
71. The human growth hormone gene locus: Structure, evolution, and allelic variations
72. Molecular weight of human placental lactogen investigated by gel filtration
73. Molecular weight of bovine growth hormone
74. Molecular cloning of DNA complementary to bovine growth hormone mRNA
75. Human growth hormone and extracellular domain of its receptor: Crystal structure of the complex
76. Three-dimensional structure of a genetically engineered variant of porcine growth hormone
77. The prolactin/growth hormone receptor family
78. Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis
79. Glycine 119 of bovine growth hormone is critical for growth-promoting activity
80. A growth hormone (GH) analog can antagonize the ability of native GH to promote differentiation of 3T3-F442A preadipocytes and stimulate insulin-like and lipolytic activities in primary rat adipocytes
81. Use of functionalized polyethylene glycols for modification of polypeptides
82. Peg-modified proteins
83. Rational design of potent antagonists to the human growth hormone receptor
84. Rational design of receptor-specific variants of human growth hormone
85. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
86. Effects of estradiol and exogenous insulin-like growth Factor I (IGF-I) on the IGF-I axis during growth hormone inhibition and antagonism
87. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH
88. A six week, double blind, placebo controlled study of a growth hormone antagonist, B2036-PEG (Trovert) in acromegalic patients
89. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors
90. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs
91. Confusion in clinical and laboratory GH and IGF-I reports
92. The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic-pituitary disease
93. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human
94. Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice
95. A selective recombinant human (rh) GH-receptor antagonist fails to impede metabolic removal of endogenous or exogenous GH in healthy adults: Evidence that the GH receptor does not participate primarily in the in process
96. MRI morphologic analysis of GH-secreting tumor response to growth hormone receptor antagonist therapy
97. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient
98. The Wisconsin epidemiological study of diabetic retinopathy: A review
99. The Houssay phenomenon in man: Recovery from retinopathy in a case of diabetes with Simmond's disease
100. Diabetic retinopathy. II. Comparison of disease remission induced by various degrees of pituitary ablation by Y90
101. Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy
102. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization
103. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects
104. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: A randomized controlled study
105. Efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: A randomized controlled study
106. Essential role of growth hormone in ischemia-induced retinal neovascularization
107. Glomerular hyperfiltration in insulin-dependent diabetes mellitus is correlated with enhanced growth hormone secretion
108. Functional and structural changes of the kidney in acromegaly
109. A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin
110. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin secretion in experimental diabetes in mice
111. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice
112. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
113. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer
114. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer
115. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast
116. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study
117. The growth hormone receptor antagonist B2036-PEG (Trovert) inhibits the growth of breast cancer xenografts in nude mice